无载体放射性碘标记间碘苄胍的制备和应用研究进展

doi:10.7538/tws.2017.30.01.0054

摘要/Abstract

摘要：

放射性碘标记间碘苄胍（［*I］MIBG）在神经内分泌肿瘤和心脏病的诊断，以及神经内分泌肿瘤的治疗方面起着重要作用。高比活度无载体放射性碘标记MIBG（no-carrier-added (n.c.a.) ［*I］MIBG）克服了目前商用放射性碘标记MIBG（carrier-added(c.a.) ［*I］MIBG）的缺点，有利于临床使用。近20年来，无载体放射性碘标记MIBG的制备和应用研究逐渐得到重视，并取得了重要进展。本文对无载体放射性碘标记MIBG的制备方法进行了总结，对n.c.a. ［*I］MIBG和c.a. ［*I］MIBG诊断与治疗方面的特点进行了对比，同时介绍了其在临床研究方面的最新进展。

关键词: 间碘苄胍, 无载体, 高比活度, 诊断, 放射性治疗

Abstract:

Radioiodinated metaiodobenzylguanidine (MIBG) is an important diagnostic agent for oncology and cardiology, or as a targeted radiotherapeutic for neuroendocrine tumors. Commercial formulations of radioiodinated MIBG (carrier-added (c.a.) ［*I］MIBG) contain large mass amount of unlabeled MIBG, which is disadvantage to diagnosis or therapy with adverse effects in patients. High specific activity no-carrier-added radioiodinated MIBG ( n.c.a. ［*I］MIBG) has the advantage of lower risk of adverse effects and is more suitable for clinical diagnostic and therapy. Much importance was attached to the preparation and application of n.c.a. ［*I］MIBG, and great achievements had been made in the last 20 years. Here we considered the methods of preparation of n.c.a.［*I］MIBG, comparison of n.c.a. ［*I］MIBG and c.a. ［*I］MIBG in diagnostic and therapy, and the clinical status of n.c.a. ［*I］MIBG.

Key words: meta-iodobenzylguanidine, no-carrier-added, high specific activity, diagnostic, radiotherapy

樊彩云;邓新荣;罗志福. 无载体放射性碘标记间碘苄胍的制备和应用研究进展[J]. 同位素, 2017, 30(1): 54-62.

FAN Cai-yun;DENG Xin-rong;LUO Zhi-fu. Progress of Preparation and Applications of No-Carrier-Added Radioiodinated MIBG[J]. Journal of Isotopes, 2017, 30(1): 54-62.

参考文献

［1］罗全勇. MIBG及其衍生物的研究进展［J］. 国外医学•放射医学核医学分册，2002，26：216-219.Luo Quanyong. The recent research progress of MIBG and its derivatives［J］. Foreign Medicine Science Section of radiation Medicine and Nuclear Medicine, 2002, 26: 216-219.
［2］Vallabhajosula S, Nikolopoulou A. Radioiodinated Metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology［J］. Semin Nucl Med, 2011, 41: 324-333.
［3］Boyd M, Ross S, Owens J, et al. Preclinical evaluation of no-carrier-added［¹³¹I］ meta-iodobenzyl guanidine, for the treatment of tumours transfected with the noradrenaline transporter Gene［J］. Lett Drug Des Disc, 2004, 1: 50-57.
［4］Wafelman A R, Konings M C P, Hoefnagel C A, et al. Synthesis, radiolabelling, and stability of radioiodinated m-iodobenzylguanidine, a review［J］. Appl Radiat Isot, 1994, 45: 997-1007.
［5］Knickmeier M, Mathejia P, Wichter T, et al. Clinical evaluation of no-carrier-added meta-［¹²³I］iodobenzylguanidine for myocardial scintigraphy［J］. Eur J Nucl Med, 2000, 27: 302-307.
［6］Bomanji J, Levison D A, Flatman W D, et al. Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: A histopathological comparison［J］. J Nucl Med, 1987, 28: 973-978.
［7］Mairs R J, Boyd M. Optimizing MIBG therapy of neuroendocrine tumors: Preclinical evidence of dose maximization and synergy［J］. Nucl Med Biol, 2008, 35: 9-20.
［8］Tobes M C, Jaques S, Wieland D M, et al. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine［J］. J Nucl Med, 1985, 26: 897-907.
［9］Sisson J C, Wieland D M, Sherman P, et al. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function［J］. J Nucl Med, 1987, 28: 620-1624.
［10］Nakajo M, Shimabukuro K, Yoshimura H, et al. Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart［J］. J Nucl Med, 1986, 27: 84-89.
［11］Smets L A, Loesberg C, Janssen M, et al. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SKNSH cells［J］. Cancer Res, 1989, 49: 2941- 2944.
［12］Ehninger G, Klingebiel T, Schuler U, et al. Stability and pharmacokinetics of m-［¹³¹I］- iodobenzylguanidine in patients［J］. Cancer Res, 1987, 47: 6147-6149.
［13］Barrett J A, Loyal J L, Hillier S M, et al. Comparison of high-specific-activity ultratrace ^123/131I-MIBG and carrier added ^123/131I-MIBG on efficacy, pharmacokinetics , and tissue distribution［J］. Cancer Biother Radiopharma, 2010, 25: 299-308.
［14］Vaidyanathan G, Zalutsky M. No-carrier-added synthesis of meta-［¹³¹I］ iodobenzyl guanidine［J］. Appl Radiat Isot, 1993, 44: 621-628.
［15］He Y, Das B, Baruchel S, et al. Meta-［¹²³I］ iodobenzylguanidine is selectively radiotoxic to neuroblastoma cells at concentrations that spare cells of haematopoietic lineage［J］. Nucl Med Commun, 2004, 25: 1125-1130.
［16］Samnick S, Bader J B, Müller M, et al. Improved labelling of no-carrier-added ¹²³I-MIBG and preliminary clinical evaluation in patients with ventricular arrhythmias［J］. Nucl Med Commun, 1999, 20: 537-545.
［17］Vaidyanathan G, Affleck J D, Alstonk K L, et al. A tin precursor for the synthesis of no-carrier-added ［*I］MIBG and ［²¹¹At］MABG［J］. J Label Compd Radiopharm, 2007, 50: 177-182.
［18］Rossouw D D, Macheli L. Large-scale synthesis of no-carrier-added ［¹²³I］MIBG, using two different stannylated precursors［J］. J Label Compd Radiopharm, 2009, 52: 499-503.
［19］Verberne H J, Bruin K, Habraken J B A, et al. No-carrier-added versus carrieradded ¹²³I-metaiodobenzylguanidine for the assessment of cardiac sympathetic nerve activity［J］. Eur J Nucl Med Mol Imaging, 2006, 33: 483-490.
［20］Hunter C, Zhu X. Polymer-supported radiopharmaceuticals: ［¹³¹］MIBG and ［¹²³］MIBG［J］. J Label Compd Radiopharma, 1999, 42: 653-661.
［21］Donovan A C, Valliant J F. A convenient solution-phase method for the preparation of meta iodobenzylguanidine in high effective specific activity［J］. Nucl Med Biol, 2008, 345: 741-746.
［22］Donovan A C, Forbes J, Dorff P, et al. A new strategy for preparing molecular imaging and therapy agents using fluorine-rich (fluorous) soluble supports［J］. J Am Chem Soc, 2006, 128: 3536-3537.
［23］Donovan A C, Valliant J F. Soluble supports and the preparation of radiopharmaceuticals in high effective specific activity［J］. J Label Compd Radiopharm, 2007, 50( Suppl 1): S30.
［24］Valliant J F, Dorff P, Chirakal R. Method for purifying radiolabeled compounds: US, 20090005545［P］ 2009-01-01.
［25］Dzandzi J P, Vera D R, Valliant J F. A hybrid solid-fluorous phase radioiodination and purification platform［J］. J Labelled Comp Radiopharm, 2014, 57: 551-557.
［26］Hu B, Blecha J, Neumann K, et al. A new efficient synthesis of no carrier added radioiodinated tracers［J］. J Nucl Med, 2014, 55 (Suppl 1): 1181.
［27］Vaidyanathan G, Zalutsky M. No-carrier-added meta-［¹²³I］iodobenzylguanidine: synthesis and preliminary evaluation［J］. Nucl Med Biol, 1995, 22: 61-64.
［28］Kinckmeier M, Schafers M, Schober O. Two years’ experience using no-carrier-added meta-［¹²³I］iodobenzylguanidine in clinical studies［J］. Eur J Nucl Med, 2001, 28: 1437.
［29］Mairs R J, Russell R, Cunningham S, et al. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added ［¹³¹I］meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma［J］. Eur J Cancer, 1995, 4: 576-581.
［30］Mars R J, Cunningham S H, Russell J, et al. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation［J］. J Nucl Med, 1995, 36: 1088-1095.
［31］James O, Colleman R E. Radioiodinated MIBG in paraganglioma and pheochromocytoma: previous results and early experiences using no-carrier-added MIBG［J］. Nucl Med Biol, 2008, 35(S1): 63-76.
［32］Matthay K K, Weiss B, Villablanca J G, et al. Dose escalation study of no-carrier-added ¹³¹I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial［J］. J Nucl Med, 2012, 53: 1155-1163.
［33］Coleman R E, Stubbs J B, Barrett J A, et al. Radiation dosimetry, pharmacokinetics, and safety of ultratrace iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid［J］. Cancer Biother Radiopharm, 2009, 24: 469-475.
［34］Owens J, Bolster A A, Prosser J E, et al. No-carrier-added 123I-MIBG: an initial clinical study in patients with phaeochromocytoma［J］. Nucl Med Commun, 2000, 21: 437-440.
［35］Verberne H J, Sokole E B, Moerkerke A F, et al. Clinical performance and radiation dosimetry of no-carrier-added vs carrier-added ¹²³I-metaiodobenzylguanidine (MIBG) for the assessment of cardiac sympathetic nerve activity［J］. Eur J Nucl Med Mol Imaging, 2008, 35: 798-807.
［36］Chin B, Grasfeder L, Chen J, et al. Formulation and human distribution comparison of AdreView and Ultratrace^TM iobenguane I-123［J］. SNM Annual Meeting Abstract, 2011: 1 445.
［37］Chin B B, Kronauge J F, Femia F J, et al. Phase-1 clinical trial results of high-specific-activity carrier-free ¹²³I-iobenguane［J］. J Nucl Med, 2014, 55: 765-771.
［38］Coleman R E, Goldsmith S J, Noto R B, et al. One year follow-up for the phase I MTD study of ultratrace iobenguane I 131 in patients with malignant pheochromocytoma/paraganglioma (Pheo)［J］. Abstracts Presented at the 2nd Annual Meeting of the North American Neuroendocrine Tumor Society, Pancreas, 2010, 39: 272.
［39］Matthay K K, Weiss B D, Villablanca J, et al［J］. J Clin Oncol (Meeting Abstracts) , 2011, 29(suppl): 9512.
［40］Pryma D A, Barrett J A, Coleman R E, et al［J］. J Clin Oncol (Meeting Abstracts), 2011, 29 (suppl): e21122.
［41］Progenics pharmaceuticals relaunching registrational trial of azedra to treat pheochromocytomas［EB/OL］. http:∥files.shareholder.com/downloads/[JP+1]PGNX/694873273x0x708991/C7A92F01-C92E-446B-A1D2-43D8954DCB5C/PGNX_News_2013_11_25_Clinical_Trials.pdf.
［42］Progenics announces breakthrough therapy designation for azedra in pheochromocytoma and paraganglioma［EB/OL］.http:∥files.shareholder. com/downloads/PGNX/694873273x0x841459/31CA6-FD0-DD44-4414-A0A2-66F77163DD06/PGNX_News_2015_7_28_Earnings.pdf.

[1]	张锦明;杜进. 中国放射性药物制备的现状及展望[J]. 同位素, 2019, 32(3): 178-185.
[2]	田佳乐;贾红梅. ^99mTc-放射性药物的现状和展望[J]. 同位素, 2018, 31(3): 143-156.
[3]	尤林怡;郭志德;张现忠. 诊断用放射性药物研究现状与展望[J]. 同位素, 2017, 30(4): 292-306.
[4]	张健;王宁;成伟华;李忠勇;王晓静. ^99mTc标记生长抑素类似物KE108的制备及生物学评价[J]. 同位素, 2017, 30(1): 1-8.
[5]	卢霞;孟晶晶;解小芬;王蒨. SPECT V/Q断层显像半定量分析联合测定血浆D-二聚体诊断肺栓塞的价值[J]. 同位素, 2016, 29(4): 204-208.
[6]	樊彩云;邓新荣;刘子华;李凤林;罗志福. 无载体放射性碘标记MIBG的制备及初步生物分布[J]. 同位素, 2015, 28(3): 148-154.
[7]	曹瑛;邱小平;葛双. 放射性核素在核医学应用中的辐射剂量估算[J]. 同位素, 2015, 28(3): 171-177.
[8]	陈宇琼;朱清峰;李国祥;黄火强. 放射免疫分析与化学发光免疫检测应用对比及发展趋势[J]. 同位素, 2014, 27(3): 188-192.
[9]	姚宁;王荣福. 纳米载体系统在核医学的应用[J]. 同位素, 2013, 26(4): 193-197.
[10]	作者. ~(18)FDG-PET在胃癌诊断中的应用价值[J]. 同位素, 2004, 17 (1 ): 27-27 .
[11]	作者. ~(18)FDG-PET在胃癌诊断中的应用价值[J]. 同位素, 2004, 17 (1 ): 27-27 .
[12]	作者. ~(131)I的甲状腺击晕效应[J]. 同位素, 2002, 15 (1 ): 42-42 .
[13]	作者. 高比活度〔甲基-~3H〕-胸腺嘧啶核苷的制备 [J]. 同位素, 2001, 14(Z1 ): 205-205 .
[14]	作者. 高比活度硼氚化钠的制备及其应用 [J]. 同位素, 2001, 14(Z1 ): 210-210 .
[15]	作者. β_2-MG、AlbRIA在肾病诊断中的应用 [J]. 同位素, 2001, 14(2 ): 119-119 .